Cargando…
Obesity in cystic fibrosis
The prevalence of obesity in patients with cystic fibrosis (CF) is increasing and around one-third of adults with CF are now overweight or obese. The causes of excess weight gain in CF are likely multifactorial, including: adherence to the high-fat legacy diet, reduced exercise tolerance, therapeuti...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8626670/ https://www.ncbi.nlm.nih.gov/pubmed/34868883 http://dx.doi.org/10.1016/j.jcte.2021.100276 |
_version_ | 1784606700743950336 |
---|---|
author | Kutney, Katherine A. Sandouk, Zahrae Desimone, Marisa Moheet, Amir |
author_facet | Kutney, Katherine A. Sandouk, Zahrae Desimone, Marisa Moheet, Amir |
author_sort | Kutney, Katherine A. |
collection | PubMed |
description | The prevalence of obesity in patients with cystic fibrosis (CF) is increasing and around one-third of adults with CF are now overweight or obese. The causes of excess weight gain in CF are likely multifactorial, including: adherence to the high-fat legacy diet, reduced exercise tolerance, therapeutic advances, and general population trends. Increased weight has generally been considered favorable in CF, correlating with improved pulmonary function and survival. While the optimal BMI for overall health in CF is unknown, most studies demonstrate minimal improvement in pulmonary function when BMI exceeds 30 kg/m(2). Dyslipidemia and cardiovascular disease are important co-morbidities of obesity in the general population, but are uncommon in CF. In people with CF, obesity is associated with hypertension and higher cholesterol levels. With longer life expectancy and rising obesity rates, there may be an increase in cardiovascular disease among people with CF in coming years. Overweight CF patients are more likely to be insulin resistant, taking on features of type 2 diabetes. Treating obesity in people with CF requires carefully weighing the metabolic risks of overnutrition with the impact of low or falling BMI on lung function. This article describes current knowledge on the epidemiology, causes, consequence, and treatment of obesity in people with CF. |
format | Online Article Text |
id | pubmed-8626670 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Elsevier |
record_format | MEDLINE/PubMed |
spelling | pubmed-86266702021-12-02 Obesity in cystic fibrosis Kutney, Katherine A. Sandouk, Zahrae Desimone, Marisa Moheet, Amir J Clin Transl Endocrinol Special Issue: CF Endocrinology Advance The prevalence of obesity in patients with cystic fibrosis (CF) is increasing and around one-third of adults with CF are now overweight or obese. The causes of excess weight gain in CF are likely multifactorial, including: adherence to the high-fat legacy diet, reduced exercise tolerance, therapeutic advances, and general population trends. Increased weight has generally been considered favorable in CF, correlating with improved pulmonary function and survival. While the optimal BMI for overall health in CF is unknown, most studies demonstrate minimal improvement in pulmonary function when BMI exceeds 30 kg/m(2). Dyslipidemia and cardiovascular disease are important co-morbidities of obesity in the general population, but are uncommon in CF. In people with CF, obesity is associated with hypertension and higher cholesterol levels. With longer life expectancy and rising obesity rates, there may be an increase in cardiovascular disease among people with CF in coming years. Overweight CF patients are more likely to be insulin resistant, taking on features of type 2 diabetes. Treating obesity in people with CF requires carefully weighing the metabolic risks of overnutrition with the impact of low or falling BMI on lung function. This article describes current knowledge on the epidemiology, causes, consequence, and treatment of obesity in people with CF. Elsevier 2021-11-17 /pmc/articles/PMC8626670/ /pubmed/34868883 http://dx.doi.org/10.1016/j.jcte.2021.100276 Text en © 2021 The Author(s) https://creativecommons.org/licenses/by/4.0/This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Special Issue: CF Endocrinology Advance Kutney, Katherine A. Sandouk, Zahrae Desimone, Marisa Moheet, Amir Obesity in cystic fibrosis |
title | Obesity in cystic fibrosis |
title_full | Obesity in cystic fibrosis |
title_fullStr | Obesity in cystic fibrosis |
title_full_unstemmed | Obesity in cystic fibrosis |
title_short | Obesity in cystic fibrosis |
title_sort | obesity in cystic fibrosis |
topic | Special Issue: CF Endocrinology Advance |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8626670/ https://www.ncbi.nlm.nih.gov/pubmed/34868883 http://dx.doi.org/10.1016/j.jcte.2021.100276 |
work_keys_str_mv | AT kutneykatherinea obesityincysticfibrosis AT sandoukzahrae obesityincysticfibrosis AT desimonemarisa obesityincysticfibrosis AT moheetamir obesityincysticfibrosis |